T. Rowe Price Associates

Activity from announced rounds

Activity in this selectionJul 31, 2026 · Jul 1, 2026
Rounds participated in
2
Confirmed lead rounds
—
2 roles undisclosed
New companies
2
First participation on record · 0 follow-on
Funding in participating rounds
$815M
2 disclosed · full round size, not this investor’s share

By stage

Series C+2

By primary sector

Biotech1
Space tech1

By country

Australia1
United States1

Rounds

2 in this selection
K2 Space

Manufactures large, high-power satellites.

$500MSeries D
Role not disclosed
AdvanCell

AdvanCell develops targeted alpha radiopharmaceuticals for cancer using Lead-212, with integrated isotope supply and manufacturing.

$315MSeries D
Role not disclosed